| Sep'18 | Sep'17 | Sep'16 | Sep'15 | Sep'13 | Jun'13 | Sep'12 | Jun'12 | Mar'12 | Dec'11 | Sep'11 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 69,504 | 64,497 | 0 | 0 | 0 |
Direct costs | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 15,297 | 14,403 | 0 | 0 | 0 |
Gross profit | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 54,207 | 50,094 | 0 | 0 | 0 |
Operating (expenses)/income, net | ||||||||||
Research and development | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 1,272 | 1,279 | 0 | 0 | 0 |
Sales and marketing | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 12,088 | 10,788 | 0 | 0 | 0 |
General and administrative | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 15,831 | 14,581 | 0 | 0 | 0 |
Total operating expenses, net | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 29,191 | 26,648 | 0 | 0 | 0 |
Operating income | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 25,016 | 23,446 | 0 | 0 | 0 |
Other income/(expenses), net | ||||||||||
Interest income | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 2,247 | 2,152 | 0 | 0 | 0 |
Interest expense | ||||||||||
- | - | 0 | 0 | 0 | 0 | 4,104 | 2,049 | 0 | 0 | 0 |
Foreign currency exchange gains/(losses) | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 568 | -216 | 0 | 0 | 0 |
Unrealized holding loss for equity securities | ||||||||||
0 | - | - | - | - | - | - | - | - | - | - |
Dividend income | ||||||||||
0 | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - |
Impairment loss on available-for-sale equity securities | ||||||||||
- | - | - | 0 | - | - | - | - | - | - | - |
Others | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | -57 | 120 | 0 | 0 | 0 |
Total other income/(expenses), net | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | -965 | 388 | 0 | 0 | 0 |
Income before income tax | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 24,051 | 23,834 | 0 | 0 | 0 |
Income tax expense | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 2,713 | 2,792 | 0 | 0 | 0 |
Net income | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 21,338 | 21,042 | 0 | 0 | 0 |
Net income attributable to non-controlling interests | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 1,598 | 0 | 0 | 0 | - |
Income attributable to noncontrolling interests | ||||||||||
- | - | - | - | - | - | - | - | - | - | 0 |
Net income attributable to Global Cord Blood Corporation's shareholders | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 19,740 | 19,455 | 0 | 0 | 0 |
Earnings per share: | ||||||||||
Basic | ||||||||||
0.08 | 0.09 | 0.03 | 0.04 | 0.05 | 0.07 | 0.05 | 0.06 | 0.06 | 0.09 | 0.05 |
Diluted | ||||||||||
0.08 | 0.09 | 0.03 | 0.04 | 0.05 | 0.07 | 0.05 | 0.06 | 0.06 | 0.09 | 0.05 |
Other comprehensive (losses)/income, net of nil income taxes | ||||||||||
Foreign currency translation adjustments | ||||||||||
0 | 0 | 0 | 0 | - | - | - | - | - | - | - |
Unrealized holding gains/(losses) in available-for-sale equity securities | ||||||||||
- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
- Net effect of foreign currency translation, net of nil tax | ||||||||||
- | - | - | - | 0 | 0 | 0 | 0 | - | - | - |
Reclassification adjustment for loss included in net income | ||||||||||
- | - | - | 0 | - | - | - | - | - | - | - |
Total other comprehensive (losses)/income | ||||||||||
0 | 0 | 0 | - | - | - | - | - | - | - | - |
Comprehensive income | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
Comprehensive income attributable to non-controlling interests | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
Comprehensive income attributable to Global Cord Blood Corporation's shareholders | ||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |